Tag: monomethyl auristatin E
AstraZeneca Enters License Agreement with KYM Biosciences for CMG901
AstraZeneca has signed an exclusive global license agreement with KYM Biosciences, a joint venture of Keymed Biosciences and Lepu Biopharma, for CMG901.
First Patient Dosed with PRO1184 and PRO1160 Cleared for Study Initiation...
Dosing has initiated in the Phase 1 first-in-human clinical trial of PRO1184 (NCT05579366), an antibody-drug conjugates or ADC being developed by ProfoundBio comprising a folate receptor alpha-directed antibody conjugated to the exatecan payload using a novel, proprietary hydrophilic linker.
Stable, Site-Specific ADC Conjugation with SMARTag® Technology and Innovative Linker
Antibody-drug conjugates have achieved commercial success over the last 10 years with 15 therapies launched globally to date, including 11 with U.S. FDA approval, and two biosimilars. With their ability to direct highly potent cytotoxic payloads selectively to target cells, ADCs offer the prospect of more precise treatments and a reduction in off-target effects.
Zai Lab to Commercialize and Expand Patient Access to Tisotumab...
Zai Lab, a patient focused, global biopharma company committed to driving the next wave of healthcare innovation confirmed that it had signed an exclusive collaboration and...
European Medicines Agency Recommends Approval of Enfortumab Vedotin Monotherapy for Locally...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has confirmed its previously adopted positive opinion, recommending approval...
Himalaya Therapeutics to Develop Conditionally Active Biologics for the Greater China...
Clinical-stage biopharmaceutical company Himalaya Therapeutics, focused on development and commercialization in Greater China, of a novel class of investigational antibody therapeutics for the treatment...
Enfortumab Vedotin Receives Regular Approval and an Expanded Indication for Locally...
The U.S. Food and Drug Administration (FDA) has granted regular approval for enfortumab vedotin-ejfv (Padcev®; Astellas Pharma and Seagen) while, at the same time,...
Merck Acquires VelosBio and Strengthens Oncology Pipeline with Investigational Antibody-Drug Conjugates
Merck & Co (MSD) has agreed to acquire VelosBio, a privately held clinical-stage biopharmaceutical company, for U.S. $ 2.75 billion in cash, subject to...
A Novel Platform for the Generation of Site-Specific Antibody−drug Conjugates
Antibody-drug conjugates (ADCs) combine the superior selectivity of antibodies with the high potency of cytotoxic agents. With 9 approved and commercially available ADCs for...
ESMO 2020: Study Shows Meaningful Clinical Activity with Tisotumab Vedotin ...
Tisotumab vedotin, an investigational agent is being developed by Seattle Genetics and Genmab, shows meaningful clinical activity as monotherapy in patients with previously treated...
